| Revenue | SEK 0 | — |
| EBITDA | SEK -45K | -35% |
| Net profit | SEK -315K | -4% |
| Total assets | SEK 2,4M | -10% |
| Equity | SEK 1,6M | -16% |
| Employees | 0 | — |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | 0 | — | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −2 | −220 | −423 | −307 | −57 | −36 | 0 | −32 | −33 | −45 |
| Depreciation & amort. | −0 | −0 | −24 | −270 | −270 | −270 | — | −270 | −270 | −270 |
| EBIT | −2 | −220 | −447 | −577 | −327 | −306 | 0 | −302 | −303 | −315 |
| Net financials | — | −17 | 17 | −2 | — | — | — | — | 0 | −0 |
| Profit before tax | −2 | −237 | −430 | −579 | −327 | −306 | 0 | −301 | −303 | −315 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | — | −0 | — | — |
| Net profit | −2 | −237 | −430 | −579 | −327 | −306 | — | −301 | −303 | −315 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 45 | 1 191 | 5 454 | 4 188 | 3 948 | 3 639 | — | 2 895 | 2 623 | 2 358 |
| Equity | 45 | 48 | 4 248 | 3 669 | 3 342 | 3 036 | — | 2 239 | 1 936 | 1 621 |
| Long-term debt | 0 | 505 | 0 | 0 | 0 | 0 | — | 0 | — | — |
| Short-term debt | 0 | 638 | 1 206 | 519 | 606 | 604 | — | 656 | 687 | 738 |
| Total debt | — | 1 143 | 1 206 | 519 | 606 | 604 | — | 656 | 687 | 738 |
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Akloma BioScience Aktiebolag | Company | 68.0% | 68.0% | 2025 |
| Person | Role here | Other companies |
|---|---|---|
| Dan Ebbe Damm | Board of Directors | 0 companies |
| Per Jörgen Ringman | Chairman | 0 companies |
| Karl Axel Joachim Hjerpe | Board of Directors | 0 companies |